• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 18.14
  • VXN 24.38
  • VXO 19.94
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
Refresh      
VNDA (Vanda Pharmaceuticals Inc.)
Last Trade 23.88 Dividend/Share 0 PE Ratio 99.5
Date November 16-2018 Dividend Yield 0.000 Return on Assets 5.03
Change 0.05 ExDividend Date 0 Return on Capital null
Bid null Latest EPS -0.34 Price/Sale 6.780
Ask null LatestEPS Date 2017-12-31 Price to Book 4.78
Volume null EPS ttm 0.24000000000000002 Institutional % 147
Avg Volume 0.66M Shares Outstanding 52.45M Insider % 4.2
Open 23.67 Float 50.27M Short Ratio null
Prev Close 23.83 Return On Equity 6.64 5 Year Change % 0.967
High 24.06 Consensus EPS -0.05 2 Year Change % 0.401
Low 23.46 No. of Estimate 2.000 1 Year Change % 0.844
52 Week High 25.07 EPS Surprise $ null YTD Change % 0.531
52 Week Low 12.7 EPS Surprise Percent 360 6 Month Change % 0.413
52 Week Change 80.226 EBITDA -1.38M 3 Month Change % 0.093
50 Day MA 21.2478 Revenue 44.28M 1 Month Change % 0.051
200 Day MA Gross Profit 39.49M 5 Day Change % 0.056
Market Cap 1252.5M Cash 143.41M 30 Day Change % 0.038
Beta 0.802157 Debt 0M Stock Exchange NASDAQ Global Market
Sector Healthcare Revenue Per Share 1 Short Interest 0
Short Date 0 Revenue Per Employee 162183 Short Ratio null
Company Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of clinical-stage products for various central nervous system disorders. Its lead product includes Fanapt for the acute treatment of schizophrenia in adults. The company is developing Tasimelteon, which is in the orphan designation status for the treatment of non-24 hour sleep/wake disorder in blind individuals without light perception. It is also developing Tasimelteon in Phase II trials for the treatment of depression. The company was incorporated in 2002 and is headquartered in Rockville, Maryland.